Aponermin Application Scope

Aponermin is a first-in-class DR4/DR5 agonist and recombinant TRAIL-based therapy approved in China for treating relapsed or refractory multiple myeloma by inducing tumor cell apoptosis.

aponermin

Characteristics

Ingredients: Recombinant circularly permuted human TRAIL peptide

Properties: A recombinant allosteric TRAIL, stable homotrimer with high affinity to DR4/DR5, inducing caspase-mediated apoptosis
Packaging Specification: Single-use vials (exact volume unspecified in public sources)
Storage: Standard requirements per NMPA; details not explicitly disclosed in sources

Expiry Date: Refer to labeling; typical shelf-life per Chinese regulations
Executive Standard: Approved by China’s NMPA under biologics standards – classified as a Class I biological new drug
Approval Number: Granted marketing authorization by China NMPA on Nov 1, 2023
Date of Revision: First approval date is Nov 1, 2023; any further revisions not yet disclosed in public domain

Manufacturer: Wuhan Hiteck Biological Pharma Co., Ltd (via Beijing Sunbio Biotech)

Guidelines for the Use of Aponermin

Dosage and Administration:
- 10 mg/kg IV infusion once daily on days 1–5 of a 28‑day cycle
- Infuse over 90 ± 15 minutes (initial rate ≤30 drops/min for first 30 min, then normal rate)

Adverse Reactions: Common: Transient hepatotoxicity (elevated ALT/AST/LDH), neutropenia, pneumonia, hyperglycemia (Grade 1–2 mostly)
Contraindications: Not explicitly stated; likely hypersensitivity to TRAIL components (standard for biologics)
Precautions: Monitor liver function and blood counts closely during treatment

Aponermin Interactions

Drug Interactions:
- No formal interaction studies.
- Animal data show no significant pharmacokinetic changes when combined with thalidomide/dexamethasone

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.